Glucagon-like peptide-1 receptor (GLP1R) agonists have been demonstrated to be potential neuroprotective agents in a variety of CNS disorders (Harkavyi and Whitton, 2010; Athauda and Foltynie, 2016) and recent evidence indicates that NLY01 (a GLP1R agonist) directly prevents the microglia-mediated conversion of astrocytes to the A1 phenotype and is neuroprotective (Yun et al., 2018). The gene discussed is GLP1R; the disease is central nervous system disorder.